Quality assessment of critical and non-critical domains of systematic reviews on artificial intelligence in gliomas using AMSTAR II: A systematic review

IF 1.9 4区 医学 Q3 CLINICAL NEUROLOGY Journal of Clinical Neuroscience Pub Date : 2024-11-29 DOI:10.1016/j.jocn.2024.110926
Umar Ahmed Siddiqui , Roua Nasir , Mohammad Hamza Bajwa , Saad Akhtar Khan , Yusra Saleem Siddiqui , Zenab Shahzad , Aabiya Arif , Haissan Iftikhar , Kiran Aftab
{"title":"Quality assessment of critical and non-critical domains of systematic reviews on artificial intelligence in gliomas using AMSTAR II: A systematic review","authors":"Umar Ahmed Siddiqui ,&nbsp;Roua Nasir ,&nbsp;Mohammad Hamza Bajwa ,&nbsp;Saad Akhtar Khan ,&nbsp;Yusra Saleem Siddiqui ,&nbsp;Zenab Shahzad ,&nbsp;Aabiya Arif ,&nbsp;Haissan Iftikhar ,&nbsp;Kiran Aftab","doi":"10.1016/j.jocn.2024.110926","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Gliomas are the most common primary malignant intraparenchymal brain tumors with a dismal prognosis. With growing advances in artificial intelligence, machine learning and deep learning models are being utilized for preoperative, intraoperative and postoperative neurological decision-making. We aimed to compile published literature in one format and evaluate the quality of level 1a evidence currently available.</div></div><div><h3>Methodology</h3><div>Using PRISMA guidelines, a comprehensive literature search was conducted within databases including Medline, Scopus, and Cochrane Library, and records with the application of artificial intelligence in glioma management were included. The AMSTAR 2 tool was used to assess the quality of systematic reviews and <em>meta</em>-analyses by two independent researchers.</div></div><div><h3>Results</h3><div>From 812 studies, 23 studies were included. AMSTAR II appraised most reviews as either low or critically low in quality. Most reviews failed to deliver in critical domains related to the exclusion of studies, appropriateness of <em>meta</em>-analytical methods, and assessment of publication bias. Similarly, compliance was lowest in non-critical areas related to study design selection and the disclosure of funding sources in individual records. Evidence is moderate to low in quality in reviews on multiple neuro-oncological applications, low quality in glioma diagnosis and individual molecular markers like MGMT promoter methylation status, IDH, and 1p19q identification, and critically low in tumor segmentation, glioma grading, and multiple molecular markers identification.</div></div><div><h3>Conclusion</h3><div>AMSTAR 2 is a robust tool to identify high-quality systematic reviews. There is a paucity of high-quality systematic reviews on the utility of artificial intelligence in glioma management, with some demonstrating critically low quality. Therefore, caution must be exercised when drawing inferences from these results.</div></div>","PeriodicalId":15487,"journal":{"name":"Journal of Clinical Neuroscience","volume":"131 ","pages":"Article 110926"},"PeriodicalIF":1.9000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S096758682400465X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Gliomas are the most common primary malignant intraparenchymal brain tumors with a dismal prognosis. With growing advances in artificial intelligence, machine learning and deep learning models are being utilized for preoperative, intraoperative and postoperative neurological decision-making. We aimed to compile published literature in one format and evaluate the quality of level 1a evidence currently available.

Methodology

Using PRISMA guidelines, a comprehensive literature search was conducted within databases including Medline, Scopus, and Cochrane Library, and records with the application of artificial intelligence in glioma management were included. The AMSTAR 2 tool was used to assess the quality of systematic reviews and meta-analyses by two independent researchers.

Results

From 812 studies, 23 studies were included. AMSTAR II appraised most reviews as either low or critically low in quality. Most reviews failed to deliver in critical domains related to the exclusion of studies, appropriateness of meta-analytical methods, and assessment of publication bias. Similarly, compliance was lowest in non-critical areas related to study design selection and the disclosure of funding sources in individual records. Evidence is moderate to low in quality in reviews on multiple neuro-oncological applications, low quality in glioma diagnosis and individual molecular markers like MGMT promoter methylation status, IDH, and 1p19q identification, and critically low in tumor segmentation, glioma grading, and multiple molecular markers identification.

Conclusion

AMSTAR 2 is a robust tool to identify high-quality systematic reviews. There is a paucity of high-quality systematic reviews on the utility of artificial intelligence in glioma management, with some demonstrating critically low quality. Therefore, caution must be exercised when drawing inferences from these results.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Clinical Neuroscience
Journal of Clinical Neuroscience 医学-临床神经学
CiteScore
4.50
自引率
0.00%
发文量
402
审稿时长
40 days
期刊介绍: This International journal, Journal of Clinical Neuroscience, publishes articles on clinical neurosurgery and neurology and the related neurosciences such as neuro-pathology, neuro-radiology, neuro-ophthalmology and neuro-physiology. The journal has a broad International perspective, and emphasises the advances occurring in Asia, the Pacific Rim region, Europe and North America. The Journal acts as a focus for publication of major clinical and laboratory research, as well as publishing solicited manuscripts on specific subjects from experts, case reports and other information of interest to clinicians working in the clinical neurosciences.
期刊最新文献
Hyperoxia and unfavourable outcome in patients with non-traumatic subarachnoid haemorrhage: A systematic review and meta-analysis Safety considerations for spinal surgery in patients with deep brain stimulation devices Quality assessment of critical and non-critical domains of systematic reviews on artificial intelligence in gliomas using AMSTAR II: A systematic review The epidemiologic associations of food availability with national incidence and disability rates of idiopathic pediatric epilepsy Lessons from a web-based referral system for acute neurosurgical referrals. Part 1: System features and evaluation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1